Updated results from ALTER-H004 study: Anlotinib combined with TACE as adjuvant therapy in patients with hepatocellular carcinoma (HCC) at high risk of recurrence after surgery—A single arm, multi-center, phase II clinical trial.
Authors
Xiaojing Song (ORCID: https://orcid.org/0000-0001-9462-0056)
Lei Zhang (ORCID: https://orcid.org/0000-0002-0580-0889)
Updated results from ALTER-H004 study: Anlotinib combined with TACE as adjuvant therapy in patients with hepatocellular carcinoma (HCC) at high risk of recurrence after surgery—A single arm, multi-center, phase II clinical trial.
Xiaojing Song, Lei Zhang, Zheng Wu, Zheng Wang
Journal
Journal of Clinical Oncology
Topics
Lung Cancer Research Studies
article
Updated results from ALTER-H004 study: Anlotinib combined with TACE as adjuvant therapy in patients with hepatocellular carcinoma (HCC) at high risk of recurrence after surgery—A single arm, multi-center, phase II clinical trial.
Xiaojing Song, Lei Zhang, Zheng Wu, Zheng Wang
article en
Abstract
No abstract available for this paper.
Publication Tag
Journal of Clinical OncologyVol. 43(4_suppl)
Institutions
First Affiliated Hospital of Xi'an Jiaotong University (CN), First Hospital of Lanzhou University (CN), Lanzhou University (CN)